Navigation Links
3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/21/2013

MENLO PARK, Calif., Oct. 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pathways resulting in death of tumor cells or virally-infected cells, today presented positive data from preclinical studies of the company's novel fatty acid synthase (FASN) inhibitors. 

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO )

In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers.  FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner.  Of note, single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts.  FASN inhibition was well tolerated at dose levels that achieved potent anti-cancer effect. 

"Our novel FASN inhibitor molecules demonstrate strong single-agent anti-cancer activity in vivo, and we are excited by the potential of these drugs to halt tumor growth and progression," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  "FASN is a highly attractive target in oncology, but prior inhibitor programs have been challenged in aligning therapeutic efficacy with tolerability.  3-V's preclinical studies characterizing our FASN inhibitors point to a number of critical attributes, including potent tumor cell growth inhibition across a number of tumor types and a promising tolerability profile that should enable use in combination with standard of care.  We are ready to commence a Phase 1 clinical study for our lead candidate, TVB-2640, this year in patients with advanced solid tumors."

The company's lead clinical candidate, TVB-2640, is one of a series of FASN inhibitors initially being developed by 3-V to treat solid tumor cancers by inhibiting key metabolic and signaling pathways associated with tumor growth and proliferation.  FASN activity promotes the tumorigenic potential of cells as part of tumor cell metabolism, which in turn provides fuel required by rapidly proliferating cancer cells.  FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers.

3-V has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and plans to initiate first-in-human studies of TVB-2640 by the end of 2013.

Data for 3-V's FASN tumor metabolism inhibitors was presented during the Therapeutic Agents: session of the Molecular Targets and Cancer Therapeutics meeting on Monday at 12:30 pm ET in a poster titled "Characterization of small-molecule FASN inhibitors in preclinical tumor models" (Abstract #B261)

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The
3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

 

Contact information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):